% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Gelderblom:278647,
      author       = {H. Gelderblom and R. L. Jones and J.-Y. Blay and S. George
                      and M. von Mehren and J. R. Zalcberg and Y.-K. Kang and A.
                      A. Razak and J. Trent and S. Attia and A. Le Cesne and B. L.
                      Siontis and D. Goldstein and K. Boye and C. Sanchez and N.
                      Steeghs and P. Rutkowski and M. Druta and C. Serrano and N.
                      Somaiah and P. Chi and B. Harrow and C. Becker and W.
                      Reichmann and M. L. Sherman and R. Ruiz-Soto and M. C.
                      Heinrich and S. Bauer},
      collaboration = {I. investigators},
      title        = {{P}atient-reported outcomes and tolerability in patients
                      receiving ripretinib versus sunitinib after treatment with
                      imatinib in {INTRIGUE}, a phase 3, open-label study.},
      journal      = {European journal of cancer},
      volume       = {192},
      issn         = {0014-2964},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2023-01691},
      pages        = {113245},
      year         = {2023},
      abstract     = {In the INTRIGUE trial, ripretinib showed no significant
                      difference versus sunitinib in progression-free survival for
                      patients with advanced gastrointestinal stromal tumour
                      (GIST) previously treated with imatinib. We compared the
                      impact of these treatments on health-related quality of life
                      (HRQoL).Patients were randomised 1:1 to once-daily
                      ripretinib 150 mg or once-daily sunitinib 50 mg (4 weeks
                      on/2 weeks off). Patient-reported outcomes were assessed
                      using the European Organisation for Research and Treatment
                      of Cancer Quality of Life Questionnaire for Cancer-30 (EORTC
                      QLQ-C30) questionnaire at day (D)1, and D29 of all cycles
                      until treatment discontinuation. Change from baseline was
                      calculated. Time without symptoms or toxicity (TWiST) was
                      estimated as the mean number of days without progression,
                      death, or grade ≥3 treatment-emergent adverse events per
                      patient over 1 year of follow-up.Questionnaire completion at
                      baseline was $88.1\%$ (199/226) for ripretinib and $87.7\%$
                      (199/227) for sunitinib and remained high for enrolled
                      patients throughout treatment. Patients receiving sunitinib
                      demonstrated within-cycle variation in self-reported HRQoL,
                      corresponding to the on/off dosing regimen. Patients
                      receiving ripretinib reported better HRQoL at D29
                      assessments than patients receiving sunitinib on all scales
                      except constipation. HRQoL was similar between treatments at
                      D1 assessments, following 2 weeks without treatment for
                      sunitinib patients. TWiST was greater for ripretinib
                      patients (173 versus 126 days).Patients receiving ripretinib
                      experienced better HRQoL than patients receiving sunitinib
                      during the dosing period and similar HRQoL to patients who
                      had not received sunitinib for 2 weeks for all QLQ-C30
                      domains except constipation. Ripretinib may provide
                      clinically meaningful benefit to patients with advanced GIST
                      previously treated with imatinib.},
      keywords     = {Gastrointestinal stromal tumours (Other) / Patient reported
                      outcome measures (Other) / Protein kinase inhibitors (Other)
                      / Quality of life (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37598656},
      doi          = {10.1016/j.ejca.2023.113245},
      url          = {https://inrepo02.dkfz.de/record/278647},
}